Quarterly report · Q1
6523.TEDINET S100OZNU
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥81.5bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥340.5bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥80.9bn | 2021-04-01 → 2021-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥2.0bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥5.6bn | 2021-04-01 → 2021-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥6.3bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥14.1bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥7.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥8.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥10.4bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥7.0bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥10.4bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥595.7bn | at 2022-06-30 | Cons. | Assets IFRS |
| Total assets | ¥591.3bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥571.4bn | at 2021-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥458.0bn | at 2022-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥455.3bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥137.7bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥136.1bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥119.6bn | at 2021-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥107.6bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥136.9bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥135.4bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥119.0bn | at 2021-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥82.1bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥95.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥57.5bn | at 2021-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥1.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥51.1bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥13.8bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥5.2bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥4.7bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥11.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥7.0bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥13.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-57.26 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥89.39 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-57.26 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥86.31 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 23.0% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 22.9% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 20.8% | at 2021-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | ¥552m |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-06-30 | ¥552m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥6.7bn |
| jpcrp040300-q1r_E36976-000Diabetes Managementreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥26.5bn |
| jpcrp040300-q1r_E36976-000Diabetes Managementreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥26.5bn |
| jpcrp040300-q1r_E36976-000Diabetes Managementreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥5.5bn |
| jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥23.4bn |
| jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥23.4bn |
| jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥31.1bn |
| jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥31.1bn |
| jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.0bn |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥80.9bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥80.9bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥8.8bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | ¥940m |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2021-06-30 | ¥940m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥3.1bn |
| jpcrp040300-q1r_E36976-000Diabetes Managementreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥26.3bn |
| jpcrp040300-q1r_E36976-000Diabetes Managementreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥26.3bn |
| jpcrp040300-q1r_E36976-000Diabetes Managementreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥3.5bn |
| jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥21.9bn |
| jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥21.9bn |
| jpcrp040300-q1r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥1.7bn |
| jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥31.8bn |
| jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥31.8bn |
| jpcrp040300-q1r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥3.6bn |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥80.0bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥80.0bn |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥8.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 810
| Item | Context | Value | Unit |
|---|---|---|---|
| Income taxes refund ope cf IFRS | CurrentYTDDuration | 250000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 13788000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 1914000000 | JPY |
| Purchase of property plant and equipment and intangible assets inv cf IFRS | Prior1YTDDuration | -3439000000 | JPY |
| Purchase of property plant and equipment and intangible assets inv cf IFRS | CurrentYTDDuration | -3376000000 | JPY |
| Proceeds from sale of property plant and equipment and intangible assets inv cf IFRS | Prior1YTDDuration | 52000000 | JPY |
| Proceeds from sale of property plant and equipment and intangible assets inv cf IFRS | CurrentYTDDuration | 54000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YTDDuration | － | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYTDDuration | -1889000000 | JPY |
| Payments for acquisition of businesses inv cf IFRS | Prior1YTDDuration | -363000000 | JPY |
| Payments for acquisition of businesses inv cf IFRS | CurrentYTDDuration | － | JPY |
| Purchase of investments accounted for using equity method inv cf IFRS | Prior1YTDDuration | -982000000 | JPY |
| Purchase of investments accounted for using equity method inv cf IFRS | CurrentYTDDuration | － | JPY |
| Other inv cf IFRS | Prior1YTDDuration | -5000000 | JPY |
| Other inv cf IFRS | CurrentYTDDuration | 42000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -4737000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -5168000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | Prior1YTDDuration | -50000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | CurrentYTDDuration | 19000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1YTDDuration | 311348000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | CurrentYTDDuration | － | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -322677000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -6364000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -1329000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -1421000000 | JPY |
| Proceeds from issuance of shares fin cf IFRS | Prior1YTDDuration | － | JPY |
| Proceeds from issuance of shares fin cf IFRS | CurrentYTDDuration | 100000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | -277000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | － | JPY |
| Proceeds from sale of treasury shares fin cf IFRS | Prior1YTDDuration | 27000000 | JPY |
| Proceeds from sale of treasury shares fin cf IFRS | CurrentYTDDuration | － | JPY |
| Dividends paid to owners of parent fin cf IFRS | Prior1YTDDuration | － | JPY |
| Dividends paid to owners of parent fin cf IFRS | CurrentYTDDuration | -4220000000 | JPY |
| Other fin cf IFRS | Prior1YTDDuration | 5000000 | JPY |
| Other fin cf IFRS | CurrentYTDDuration | 0 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -12953000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | -11885000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 601000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 2031000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | -3301000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | -13108000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 60762000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 95232000000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 57460000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 82123000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E36976-000DiabetesManagementReportableSegmentMember | 26259000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E36976-000HealthcareSolutionsReportableSegmentMember | 31763000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 21946000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 79968000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | 940000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |